Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Tacrolimus is a standard and widely used maintenance immunosuppressive agent after solid
organ transplantation.The purpose of this trial is to determine if dosing of tacrolimus
through genetics will help in early attainment and maintenance of the correct dosage level in
the early post-transplant period. This pilot dose-finding trial will help to determine a
dosing strategy guided by genotypes and age for solid organ transplant recipients that will
be further validated through a multi-centre trial as an immediate next step. The study
hypothesizes that dosage levels determined through age and genotype will be attained faster
and more accurately than the standard dosing procedures in the 14-days after the transplant.
Further, this study hypothesizes that a genotype and age dosing strategy will cause a faster
recovery (tested through the kidneys' ability to clear creatine from the blood) and result in
lower frequencies of adverse effects and rejection of the transplant.